Abstract. Peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) is a key modulator of mitochondrial biogenesis. It is a coactivator of multiple transcription factors and regulates metabolic processes. However, little is known about the expression and function of PGC1α in glioblastoma multiforme (GBM), the most prevalent and invasive type of brain tumor. The purpose of the present study was to investigate the biological function, localization and expression of PGC1α in GBM. It was observed that PGC1α expression is increased in the tumor cells, and a higher level of expression was observed in the mitochondria. Bioinformatics analyses identified that metabolic and mitochondrial genes were highly expressed in GBM cells, with a high PGC1α mRNA expression. Notably, mitochondrial function-associated genes were highly expressed in cells alongside high PGC1α expression. Collectively, the results of the present study indicate that PGC1α is associated with mitochondrial dysfunction in GBM and may have a role in tumor pathogenesis and progression.
Introduction
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) regulates metabolism (1, 2) , mitochondrial biogenesis and energy homeostasis (3, 4) . A number of studies have reported PGC1α as a central regulator of thermogenesis, mitochondrial biogenesis and adaptation to fasting in brown adipose tissue, skeletal muscle, cardiac muscle and the liver (1, 5) . By contrast, PGC1α in the central nervous system is less associated with energy state or thermogenesis (6) . PGC1α expression in the central nervous system is high in the embryonic and early postnatal stages, but is decreased during maturation. PGC1α is expressed mostly by γ-aminobutyric acid-ergic neurons; however, a low level of PGC1α is also expressed in glia in the mature brain (7) . There is a significant association between PGC1α and the metabolism of reactive oxygen species. PGC1α-null mice are considerably more sensitive to the neurodegenerative effects of the oxidative stressors 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and kainic acid, which suggests that PGC1α has a role in cellular antioxidant defense (8) .
Numerous clinical studies have reported a significant association between PGC1α and a number of types of cancer. In breast, colon and ovarian cancer (9) (10) (11) (12) , a significant decrease in PGC1α expression accelerated the 'Warburg effect', which allows cancer cells to switch from mitochondrial to glycolytic metabolism to meet the metabolic requirements of proliferation (13) . By contrast, increased PGC1α expression is present in melanoma, with a corresponding decrease in patient survival (14) . The role of PGC1α in a number of cancer types remains unclear and warrants further studies.
Glioblastoma multiforme (GBM) is the most prevalent and invasive type of brain tumor. It aggressively infiltrates and spreads to the surrounding brain tissue via extensive microvascular proliferation. Numerous necrotic areas surrounded by palisading tumor cells are often observed (15) . Although novel therapeutic strategies and improved clinical diagnostics have been introduced, GBM remains one of the most fatal diseases (16) . An extensive amount of research has been Expression of PGC1α in glioblastoma multiforme patients SANG YEON CHO 1* performed to determine the mechanisms of unlimited proliferation in GBM, as well as its robust resistance to existing drugs and therapies (17, 18) In the present study, the expression of PGC1α in normal cortical tissues and GBM tissues was compared. The results of the present study indicate that PGC1α may be a novel biomarker for GBM, as well as a novel target for future GBM therapy development.
Materials and methods

Patient samples.
All experiments were performed in accordance with approved guidelines of Chungnam National University Hospital (CNUH; Daejeon, Republic of Korea). The Institutional Review Board of the CNUH approved the experimental protocols and all patients provided written informed consent prior to surgery. A total of 49 patients undergoing tumor resection surgeries at the Department of Neurosurgery, CNUH were enrolled, and pathological diagnoses were confirmed by the Department of Pathology, CNUH via immunohistochemistry. First-time GBM diagnosis was used as the selection criterion, resulting in 26 patient samples that were included in the present study (Table I ). The mean age of the patients was 58 years (range, 35 to 74 years). Normal brain tissue samples were obtained from cadavers or from autopsies of surrounding normal brain tissues of consenting GBM patients that underwent surgery (approval no. CNUH 2013-11-006).
Tissue microarray and immunostaining. Tissue microarrays (TMA) were used to perform the comparative histological analysis of normal brain and GBM tissues. The paraffin-embedded sample tissues were de-paraffinized and rehydrated in a graded alcohol series. Tissues were retrieved using 0.01 M citrate buffer (pH 6.0) and heated in a microwave vacuum histoprocessor (RHS-1; Milestone Medical, Bergamo, Italy) at a controlled temperature of 121˚C for 15 min. Following washing with phosphate-buffered saline (pH 7.4), tissue sections were incubated with anti-PGC1α antibody (1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; #SC13067) overnight in a humidity chamber at 4˚C. Immunohistochemical staining of the tissue sections was performed using avidin-biotin peroxidase complex as previously described (19, 20) . Additional TMA samples of normal cortex and GBM tissues were obtained from US Biomax, Inc. (Rockville, MD, USA).
All immunostaining was performed with antibodies that detected the N-terminal epitope of PGC1α (1:200; Santa Cruz Biotechnology, Inc.; #sc-13067). For immunofluorescence analysis, PGC1α and COX4 (1:200; Cell Signaling Technology, Inc., Danvers, MA, USA; #4D11-B3-E8) were used as above but with either a Cy3-conjugated antibody (1:500; anti-rabbit; GE Healthcare Life Sciences Chalfont, UK; #PA43004) or a Cy2-conjugated secondary antibody (1:200; anti-mouse; GE Healthcare Life Sciences; #PA42002). Cell nuclei were visualized with DAPI, and double-stained sections were visualized using an Axiophot microscope (Carl Zeiss AG, Oberkochen, Germany).
Bioinformatics. The mRNA expression of 18,988 probes from 38 GBM cell lines was analyzed using the publicly available Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) database (https://portals.broadinstitute.org/ccle/home) (21) . The level of PGC1α mRNA expression among the 38 GBM cell lines was determined using CCLE. The mRNA expression data was normalized using the RankNormalize module in GenePattern (http://www.broadinstitute.org/cancer/software/genepattern). Gene Neighbors and Class Neighbors modules in GenePattern (http://www.broadinstitute.org/cancer/software/genepattern) were used to select genes that were closely associated with PGC1α (22) . Hierarchical clustering was performed using complete linkage and Pearson rank-correlation distance with software provided by GenePattern (HierarchicalClustering; version 6). The colors in the heat-maps show the relative gene expression compared to the mean expression, with red being higher and blue lower. From the 18,988 gene set, 100 genes that were most correlated with PGC1α were selected for classification by Gene Ontology Enrichment Analysis (GO terms) using Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf. gov) (23) . Differentially expressed genes (DEGs) were classified according to GO terms based on their biological process, molecular function or cellular component. DAVID provided an overview of extensive pathways (www.biocarta.com) in which various genes interacted, as well as the number of DEGs per pathway with a P-value representing gene enrichment. Gene enrichment score with P<0.05 represents a strong association rather than random chance (23) . For genes with unknown biological processes, GeneMANIA database (http://www. genemania.org) was used to predict their function (24) .
Statistical analysis. ImageJ software (version 1.47; National Institutes of Health, Bethesda, MD, USA) was used to quantify the optical density (pixels/mm 2 ) or the intensity of images. The results from immunohistochemical staining were analyzed by a paired t-test between two groups. Data were presented as the mean ± standard error. Statistical analyses were performed using the Prism 5.0 software (GraphPad Prism Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference. Data transformation (log conversion) selection and statistical analyses were performed with either the Microsoft Excel 11.0 (Microsoft Corporation, Redmond, WA, USA) or Prism 5.0 software.
Results
PGC1α is highly and variably expressed in GBM patients.
To determine the association between PGC1α and GBM, levels of PGC1α protein in GBM and control (normal cortex) tissues were compared using publicly available TMAs from US Biomax, Inc. (Fig. 1) . PGC1α was weakly detectable in the nuclei of cortical tissues in the control, whereas it was highly and sporadically expressed throughout the GBM tissues. Furthermore, PGC1α was mostly expressed within the cytoplasm with pale nucleic density (Fig. 1A) . Bright-field immunohistochemical analysis of TMA images using a densitometer revealed that PGC1α expression varied between tumor samples (Fig. 1B) .
For additional validation, PGC1α mRNA levels were determined in GBM cell lines (n=38) using the Broad-Novartis CCLE database (21) . Comparative analysis of PGC1α expression in GBM and five other types of cancer, including liver, ovarian, endometrial, breast and prostate carcinoma revealed that although there were variations in PGC1α mRNA expression between the GBM cell lines (Fig. 1D) , the level of expression was increased in GBM compared to other cancer cell lines (Fig. 1C) . Overall, these data demonstrate that PGC1α expression was increased in a subpopulation of GBM cells.
PGC1α is localized to the mitochondria in GBM. As a transcriptional coactivator, PGC1α is reported to be localized in the nuclei of the normal cortex (25) . However, immunofluorescence analysis demonstrated localization of PGC1α in the perinuclear or cytoplasmic areas of GBM tissues ( Fig. 2A) . To confirm the subcellular localization of PGC1α, double staining with anti-PGC1α and anti-COX4 (a mitochondrial marker) antibodies was employed. There was a certain level of colocalization of PGC1α and COX4, thereby indicating that PGC1α was expressed in the mitochondria in GBM in addition to the perinuclear or cytoplasmic areas (Fig. 2B ).
Gene Neighbors of PGC1α. Bioinformatics analysis of PGC1α-associated genes was performed. PGC1α mRNA expression levels detected in the GBM cell lines (n=38 ;  Table II ) ranged from 3.71 (log 2 ) to 8.83 (log 2 ), which corresponds to a fold-change of 2.38. A total of 100 genes that were strongly correlated with PGC1α were selected using Gene Neighbors (Fig. 3A) and classified using DAVID (23) . Genes with significant differences (P<0.05) were classified into two groups based on GO terms: Biological process and cellular components (Tables III and IV) . Genes highly expressed in GBM cell lines were largely associated with the generation of metabolite precursors and energy (e.g., the hexose or monosaccharide metabolic processes), oxidation reduction (e.g., mitochondrial electron transport, nicotinamide adenine dinucleotide to ubiquinone and the oxidoreduction coenzyme metabolic process), energy derivation by the oxidation of organic compounds [e.g., acetyl-CoA metabolic and catabolic processes, oxidative phosphorylation, tricarboxylic acid (TCA) cycle, aerobic respiration and glycolysis, and coenzyme metabolic and catabolic processes (e.g., cofactor catabolic process) (Fig. 3B) . Notably, highly expressed genes were associated with the mitochondria (e.g., mitochondrial membrane, mitochondrial matrix and mitochondrial respiratory chain), organelle membranes (e.g., organelle inner membrane) and the cellular envelope (Fig. 3C ). This observation is in agreement with the finding that PGC1α is localized in the mitochondria in GBM as previously described.
PGC1α expression is highly correlated with mitochondrial function in GBM. Two-way hierarchical clustering of targeted gene sets was performed between five GBM cell lines with the highest (LNZ308, LN464, DBTRG05MG, LN235 and SNU626) and lowest levels (LN229, KNS60, SF172, SNU466 and KS1) of PGC1α expression. The expression of TCA cycle-(P<0.0001), (Fig. 4A-C) . Furthermore, the expression of antioxidant-associated genes was significantly increased in the PGC1α-upregulated cell lines compared with the PGC1α-downregulated cell lines ( Fig. 4D ; P<0.0001). Taken together, the data in Figs. 3 and 4 suggest that metabolic and mitochondrial genes were highly expressed in parallel with PGC1α. Notably, genes associated with mitochondrial functions, including TCA cycle, OXPHOS, lipogenesis and antioxidant genes, were highly expressed in cells with high PGC1α levels (Fig. 4) , which corroborates the results from a recent study (26) and the colocalization data as previously described in the present study.
Class Neighbors of PGC1α up-and downregulated GBM cell lines.
Bioinformatics analysis using Class Neighbors yielded two classes of GBM cell lines. Class A contained the ten most PGC1α-upregulated GBM cell lines, and class B contained the ten most PGC1α-downregulated GBM cell lines (Fig. 5A ). Out of a total of 18,988 probe sets, 100 genes that were most strongly correlated with classes A and B and most highly expressed were selected. DAVID analysis classified these genes into three groups based on GO terms: i) Biological process, ii) molecular function and iii) cellular components ( Fig. 5B and C ; Tables V-VIII) . GeneMANIA database analysis resulted in the identification of 52 genes with previously unknown biological interactions with PGC1α, including necdin (NDN). In addition, when genes were analyzed according to cell signaling pathway (BioCarta database), 3 signaling pathways in class A and 5 in class B were identified as statistically significant (P<0.05; Table IX ). The results of the present study demonstrate that class A genes play roles in signaling pathways associated with metabolic and mitochondrial electron transport and that class B genes are involved in signaling pathways associated with differentiation and immune function.
Discussion
The objective of the present study was to investigate the association between aberrant expression of PGC1α and GBM, and between different GBM cell lines and patients. PGC1α localization was identified to differ between GBM tissues and the normal cortex (Fig. 2) . These results corroborated with a previous study that detected a brain-specific isoform of PGC1α in the cytoplasm rather than the nucleus (27) . It was also reported that the PGC1α isoform becomes localized in the mitochondria via phosphatase and tensin homolog-induced putative kinase 1 and voltage-dependent anion channel (28) .
This present study also demonstrated that PGC1α was expressed in the mitochondria of GBM cells. Based on these Up, and down mean refers to the mean of the specific gene expression levels in the ten most PGC1a up-or downregulated cell lines.
corroborating results, it is predicted that PGC1α-mediated mitochondrial biogenesis and respiration is increased in GBM cells.
To investigate the role PGC1α has in GBM cells, several bioinformatics analyses were performed. The analyses demonstrated that metabolic and mitochondrial genes were highly correlated with PGC1α in a number of GBM cell lines. Class Neighbors analysis classified PGC1α-expressing GBM cell lines into two groups: Class A and B. Class A contained genes associated with development, neurogenesis, cell structure The dataset of significantly changed genes were identified using the Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov) (P<0.05). and motility. Class B contained genes associated with immunity, oncogenesis and signaling, including intracellular, T cell-mediated, ligand-mediated and-calcium mediated pathways. Class A genes are involved in mitochondrial and metabolic pathways, whilst class B genes are involved in differentiation and immune pathways. These data reinforce the hypothesis that PGC1α may have an important role in regulating mitochondrial and metabolic signaling pathways in the GBM microenvironment.
A notable result was the association of NDN with PGC1α. NDN is reported to function as a tumor suppressor in GBM (29) and controls the proliferation of white adipose progenitor cells (30) . NDN interacts with PGC1α via nicotinamide adenine dinucleotide dependent protein deacetylase (Sirt-1) and two transcription factors, E2F1 and P53, suggesting that interactions with these cell cycle regulating factors are key to its function (31) . Therefore, it is hypothesized that PGC1α Number of significantly changed genes per pathway. PPAR, peroxisome proliferator activated receptor; IL, interleukin 12; NF-κB, nuclear factor-κB; NK, natural killer; Th, T helper.
